Facebook
Twitter
LinkedIn
Forward
Selecting the correct on label or off label medication to treat obesity can be confusing. The acronym RXAOM provides a framework for individualizing the selection process.
|
Obesity is a metabolic disease that requires lifelong lifestyle changes and in many patients who are overweight or obese, prescription medication.
|
This case-based instructional session will be presented by quadruple board-certified psychiatrist, Dr. Tiffani Bell Washington and Dr. Sylvia Gonsahn-Bollie.
|
Here we are! At the Obesity the Tipping Point: the critical point in a process or system beyond which a significant and often unstoppable effect or change takes place.
|
This presentation will provide clinicians a brief scientific overview of 10 of the most controversial topics covered, discussed, and published in OMA’s Clinical Practice Statements, including:
|
Dr. Myriam Modestin-Sorrentino will speak on the need to raise awareness and understanding how the the obesity affects maternal and fetal health.
|
Treatment of people with unhealthy weight has typically focused on those with obesity or in those with BMI ≥ 27 with existing comorbidities; however, evidence indicates that the negative effects of
|
Demand for pharmacotherapy has increased considerably with the introduction of newer anti-obesity medications (AOM’s).
|
In adolescents and adults, the co-occurrence of eating disorders and overweight or obesity is continuing to increase.
|
Obesity is a complex phenotype reflecting the interactions of numerous genes that have been “selected” for in service of reproductive integrity with modern environments.
|